Analyzing Ascend Wellness (OTC:AAWH) & Mind Medicine (MindMed) (NASDAQ:MNMD)

Ascend Wellness (OTC:AAWHGet Free Report) and Mind Medicine (MindMed) (NASDAQ:MNMDGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Valuation and Earnings

This table compares Ascend Wellness and Mind Medicine (MindMed)’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ascend Wellness $405.93 million 0.79 -$80.90 million ($0.23) -6.78
Mind Medicine (MindMed) N/A N/A -$56.80 million ($1.88) -2.25

Mind Medicine (MindMed) has lower revenue, but higher earnings than Ascend Wellness. Ascend Wellness is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

9.7% of Mind Medicine (MindMed) shares are held by institutional investors. 24.9% of Ascend Wellness shares are held by company insiders. Comparatively, 2.1% of Mind Medicine (MindMed) shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Ascend Wellness and Mind Medicine (MindMed)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ascend Wellness -8.95% -27.55% -4.95%
Mind Medicine (MindMed) N/A -67.01% -53.15%

Analyst Ratings

This is a summary of recent ratings and target prices for Ascend Wellness and Mind Medicine (MindMed), as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascend Wellness 0 2 1 0 2.33
Mind Medicine (MindMed) 0 0 6 0 3.00

Ascend Wellness presently has a consensus price target of $2.75, suggesting a potential upside of 76.28%. Mind Medicine (MindMed) has a consensus price target of $23.50, suggesting a potential upside of 455.56%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher possible upside, analysts plainly believe Mind Medicine (MindMed) is more favorable than Ascend Wellness.

Volatility & Risk

Ascend Wellness has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500.

Summary

Mind Medicine (MindMed) beats Ascend Wellness on 8 of the 13 factors compared between the two stocks.

About Ascend Wellness

(Get Free Report)

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods. It owns, operates, and manages cannabis cultivation facilities and dispensaries in several states across the United States, including Illinois, Massachusetts, Michigan, Ohio, New Jersey, and Pennsylvania. The company's cannabis product categories include flowers, pre-rolls, concentrates, vapes, edibles, and other cannabis-related products. As of December 31, 2022, it operated 24 retail locations. The company also sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.

About Mind Medicine (MindMed)

(Get Free Report)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.

Receive News & Ratings for Ascend Wellness Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascend Wellness and related companies with MarketBeat.com's FREE daily email newsletter.